摘要
目的研究舒尼替尼治疗转移性胃癌的临床疗效及其对血小板衍生生长因子受体(PDGFR)和Notch信号通路的影响。方法纳入70例转移性胃癌患者作为研究对象,采用随机数字表法分为观察组和对照组,每组35例。两组均接受替吉奥同步放疗序贯化疗,观察组在此基础上加用舒尼替尼。比较两组治疗效果和不良反应发生情况,记录两组患者治疗前后PDGFR和Notch信号通路基因表达水平,随访记录两组患者2年总生存率。结果观察组显效率为22. 86%,对照组为5. 71%,两组间差异有统计学意义(P <0. 05)。治疗后观察组PDGFR和Notch信号通路基因阳性率分别为42. 86%和54. 29%,对照组分别为68. 57%和77. 14%,两组间差异均有统计学意义(P <0. 05)。两组治疗期间贫血、白细胞减少、胃肠道反应、口腔黏膜炎及皮肤毛发改变严重程度比较,差异无统计学意义(P> 0. 05)。两组2年生存率比较,差异无统计学意义(P> 0. 05)。结论舒尼替尼用于转移性胃癌患者能显著提高肿瘤控制效果,安全性较高,可能与其抑制PDGFR和Notch信号通路有关。
Objective To study the clinical efficacy of sunitinib in the treatment of metastatic gastric cancer and its effect on gene expression of platelet-derived growth factor receptor(PDGFR) and Notch signaling pathway. Methods Seventy patients with metastatic gastric cancer were enrolled as study subjects. They were divided into observation group and control group by random number table method, 35 cases in each group. Both groups received sequential chemo-radiotherapy with tegafur, and the observation group received sunitinib on this basis. The therapeutic effects and adverse reactions of the two groups were compared, the levels of PDGFR and Notch signaling pathway were recorded before and after treatment, the two-year overall survival rates of the two groups were recorded by follow-up. Results The effective rate of the observation group was 22. 86%, the control group was 5. 71%, the difference was statistically significant between the two groups(P < 0. 05). The positive rate of the PDGFR and Notch signaling pathway after treatment in observation group were 42. 86% and 54. 29%,the control group were 68. 57% and 77. 14%, the difference were statistically significant(P < 0. 05). There were no significant difference in the severity of anemia, leukopenia, gastrointestinal reaction,oral mucositis and skin hair changes between the two groups(P > 0. 05). There was no significant difference in the 2-year survival rate between the two groups(P > 0. 05). Conclusion Sunitinib can significantly improve the effect of tumor control in patients with metastatic gastric cancer, and has high safety, which may be related to its inhibition of PDGFR and Notch signaling pathways.
作者
王海燕
闻东
WANG Hai-yan;WEN Dong(Fuxin Central Hospital, Liaoning Province, Operating Room, 123000;Fuxin Central Hospital, Liaoning Province Oncology Surgery, 123000)
出处
《现代消化及介入诊疗》
2019年第3期249-253,共5页
Modern Interventional Diagnosis and Treatment in Gastroenterology
基金
辽宁省科学技术计划项目(2017225073)
